People affected by rosacea can experience symptoms such as facial redness, flushing, and visible blood vessels. At times, they may also develop pimples or thickened skin, especially around the nose
A new study published in the Journal of Cosmetic Dermatology found that those who used to smoke may have a higher risk of developing rosacea, but there doesn't seem to be a connection between folks who currently smoke and the skin condition.
Rosacea is a chronic inflammatory skin condition that mainly affects the face and eyes, typically in people between the ages of 30 and 50, though it can start at any age.
People affected can experience symptoms such as facial redness, flushing, and visible blood vessels. At times, they may also develop pimples or thickened skin, especially around the nose — a condition known as rhinophyma, which is more common in men.
Rosacea is generally categorized into three types: erythematotelangiectatic rosacea (ETR), papulopustular rosacea (PPR) and phymatous rosacea (PhR), with ETR being the most common.
These different types can significantly affect a person’s quality of life, often leading to anxiety, depression and low self-esteem.
There are a variety of causes to rosacea including environmental factors such as sun exposure, internal factors including immune disorders and lifestyle habits such as diet, smoking and sleep patterns.
Kent Keyser, M.D., professor of vision sciences at the University of Alabama at Birmingham, highlighted in a report in the National Rosacea Society that smoking is a major cause of vascular diseases.
Keyser noted that nicotine could contribute to the redness and visible blood vessels in rosacea by promoting the formation of new blood vessels in the skin.
Recent studies have examined the relationship between smoking and rosacea, but results have been mixed.
To better understand the connection, researchers from The First Affiliated Hospital of Zhejiang Chinese Medical University in Hangzhou, China, used Mendelian randomization (MR), an advanced genetic analysis that strengthens the causal link between exposure and outcome.
Data from genome-wide association studies (GWAS) were used in the study to examine the link between rosacea and smoking.
There were 1,195 cases on rosacea data included and 211,139 controls from the FinnGen database, while smoking data covered two groups: "previous smokers" (118,419 cases) and "current smokers" (33,928 cases) from the Neale Lab Consortium.
After analyzing data, researchers found that ex-smokers have a higher risk of developing rosacea, with a significant odds ratio of 6.77, but current smokers did not show the same significant risk.
Researchers suggest that quitting smoking might increase the chances of rosacea, although current smoking doesn't seem to have the same effect.
While the connection is still unclear due to the study relying on observational data, the use of the MR analysis made it possible to reduce bias and strengthen causal links between smoking and rosacea, with sensitivity analyses supporting the reliability of the results.
However, limitations exist as the study's focus was on European populations rather than a number of groups.
Overall, researchers suggest that although ex-smokers may have a higher risk of rosacea, people should avoid smoking from the start due to its harmful effects.
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More
Patients With Atopic Dermatitis Turn to Social Media but Trust Medical Advice Most
May 5th 2025A study found that while patients with atopic dermatitis often turn to social media for skincare advice, their decisions are most influenced by healthcare professionals, personal experience, and disease severity.
Read More
Most Patients With HS Aren’t Aware of Approved Treatments
May 1st 2025Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.
Read More